Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Operations: 2016-2025

Historic Cash from Operations for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$50.4 million.

  • Rocket Pharmaceuticals' Cash from Operations rose 3.23% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.1 million, marking a year-over-year decrease of 5.20%. This contributed to the annual value of -$209.7 million for FY2024, which is 7.60% down from last year.
  • Rocket Pharmaceuticals' Cash from Operations amounted to -$50.4 million in Q3 2025, which was down 2.97% from -$49.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Operations registered a high of -$24.3 million during Q1 2021, and its lowest value of -$57.6 million during Q1 2023.
  • Over the past 3 years, Rocket Pharmaceuticals' median Cash from Operations value was -$52.1 million (recorded in 2024), while the average stood at -$50.9 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Cash from Operations slumped by 136.03% in 2021 and then spiked by 47.63% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Cash from Operations (Quarterly) stood at -$30.9 million in 2021, then slumped by 81.06% to -$56.0 million in 2022, then skyrocketed by 47.63% to -$29.3 million in 2023, then plummeted by 60.00% to -$46.9 million in 2024, then climbed by 3.23% to -$50.4 million in 2025.
  • Its Cash from Operations was -$50.4 million in Q3 2025, compared to -$49.0 million in Q2 2025 and -$55.8 million in Q1 2025.